Aljafari, Abdulmalek

800 Background: Primary squamous cell carcinoma (SCC) of the small intestine is exceedingly rare and associated with poor prognosis. Literature is currently limited to a few case reports, and, to our knowledge, this is the first population-based analysis of patients with small intestine SCC. This study aimed to identify patient demographics and predictors of survival outcomes. Methods: Patients with histologically confirmed primary SCC of the small intestine diagnosed between 2000 and 2022 were identified from the SEER database; autopsy-only cases were excluded. Patient demographics, tumor site, stage (SEER summary stage), and initial treatments were summarized. Overall survival (OS) was defined from diagnosis to death, with one-year OS estimated by Kaplan–Meier methods. Multivariate Cox proportional hazards models evaluated associations between patient variables (age, sex, race, residence, year of diagnosis, surgery, and chemotherapy) and mortality. All statistical analyses were performed using R version 4.4.2. Results: A total of 89 patients diagnosed with primary small intestine SCC were identified. The median age at diagnosis was 68 years; 43 % were female, and 67 % were non-Hispanic White. Most patients (82 %) resided in urban counties. Tumor site was mostly the duodenum (37 %), followed by ileum (16 %) and jejunum (10 %); 33 % were not otherwise specified. Among patients with a recorded stage, 45 % had localized disease, 38 % regional disease, and 17 % distant metastases. Initial treatment comprised surgery in 60 % of patients, chemotherapy in 25 %, and radiation in 10%. The median OS was approximately six months, and the one-year OS was 36.7 % (95 % CI 27.9–48.3). Women had a higher one-year OS (42 %) than men (33 %), although this difference was not statistically significant. In multivariable analysis, surgical resection was associated with a markedly lower hazard of death (HR = 0.43, 95 % CI 0.25–0.74). Chemotherapy was associated with an insignificantly improved survival (HR 0.54, 95 % CI 0.27–1.09). Additionally, rural residence (HR ≈ 2.9) and older age (HR ≈ 1.03) were independently associated with worse survival (p<0.05). Conclusions: This population-based study highlights the rarity and aggressiveness of primary small bowel SCC, with a median OS of six months. Surgical resection was strongly associated with improved survival (adjusted HR ≈ 0.43), reinforcing its role as the cornerstone of management. Chemotherapy showed a nonsignificant survival benefit, highlighting the need for prospective studies. The association of rural residence with higher mortality suggests disparities in access to care and underscores the need for strategies to improve early detection and referral. Overall, these findings support a multimodal approach centered on surgery and warrant further studies to elucidate pathogenesis and optimize systemic therapy.

9037 Background: Efficient dissemination of research findings is critical in oncology, where timely access to new knowledge impacts clinical care and outcomes. This study analyzes publication timelines of high-impact oncology journals to identify patterns and determinants, including research categories and study designs. Methods: This is a retrospective observational study. Journals with the highest impact factors and available publication timeline data were included: Journal of Clinical Oncology, Molecular Cancer, Clinical Cancer Research, and Cancer Discovery. All articles published in 2023 were analyzed for submission-to-acceptance, acceptance-to-publication, and total publication times. Data were processed using SPSS, and statistical comparisons were made with the Kruskal-Wallis test (significance: p<0.05). Results: A total of 875 articles were analyzed. The overall median total publication time (TT) was 7.1 months (IQR: 5.7–8.9), with submission-to-acceptance (AT) and acceptance-to-publication (PT) medians of 4.8 months (IQR: 3.5–6.3) and 2.2 months (IQR: 1.6–2.6), respectively. Among journals, Molecular Cancer exhibited the shortest TT (median: 4.7 months; IQR: 3.1–6.6), while Cancer Discovery had the longest TT (median: 8.8 months; IQR: 6.8–10.6). Similarly, Molecular Cancer achieved the fastest AT (median: 3.9 months; IQR: 2.2–5.4) and PT (median: 0.6 months; IQR: 0.4–1.1). Conversely, Cancer Discovery recorded the slowest AT (median: 6.0 months; IQR: 4.5–7.8) and PT (median: 2.8 months; IQR: 2.4–3.2). In terms of research categories, blood cancer articles accounted for the largest proportion of publications (14.4%), followed by gastrointestinal cancer (13.9%). Articles in genitourinary (median TT: 6.4 months; IQR: 5.5–8.8) and cardiac cancer (median TT: 6.5 months; IQR: 5.9–6.9) categories had the shortest TT, while endocrine (median TT: 7.9 months; IQR: 5.6–10.9) and immunotherapy (median TT: 9.1 months; IQR: 6.8–10.5) categories exhibited the longest TT (p<0.05). Clinical trials were the most common study design (37.6%), followed by cross-sectional studies (19.5%). Systematic reviews had the shortest TT (median: 2.4 months; IQR: 1.9–9.2), while proof-of-concept studies required the longest TT (median: 9.5 months; IQR: 8.7–10.7) (p<0.05). Systematic reviews and database studies also had the shortest PT (median: 1.5 months), whereas proof-of-concept studies had the longest PT (median: 2.8 months; p<0.001). Conclusions: Publication timelines in oncology journals vary significantly by journal, research category, and study design. Molecular Cancer demonstrates the fastest publication processes, while Cancer Discovery exhibits the slowest. Genitourinary and dermatologic oncology categories, as well as systematic reviews, achieve the most expedited timelines, emphasizing the need to consider category and study design in publication planning.